PlasmaGen Biosciences, a Bengaluru-based biopharmaceutical firm, has raised ₹150 crore in a fresh funding round led by ViNS Bioproducts, taking its valuation past ₹1,500 crore. The infusion, joined by pharmaceutical entrepreneurs, family offices, high-net-worth individuals and existing investors, underscores growing investor interest in India’s plasma-derived therapeutics sector.
Funding bolsters manufacturing and global ambitions
The latest tranche brings PlasmaGen’s cumulative capital raised to over ₹600 crore. The company says the funds will be used to scale manufacturing capacity, pursue regulatory approvals in select overseas markets and build distribution partnerships to support international expansion.
Management also plans targeted investments in leadership, operational efficiency and product development to broaden its portfolio of plasma-derived therapies and address unmet clinical needs.
Products and domestic self-reliance
Founded in 2010, PlasmaGen develops and manufactures plasma-derived medicines including immunoglobulins, albumin, clotting factors and anti‑D immunoglobulin—therapies used for immune deficiencies, bleeding disorders, liver diseases and certain neurological conditions.
India has historically relied on imports for many of these complex biologics, which can create supply constraints and higher treatment costs. By expanding local production, companies like PlasmaGen aim to improve access, stabilise supply chains for hospitals and advance India’s broader objective of healthcare self‑reliance.
Kolar facility expands domestic capacity
A significant milestone for the company was the commercial commissioning of its plasma fractionation plant in Kolar, Karnataka, in late 2023. One of the relatively few private-sector fractionation units in the country, the facility enables large‑scale plasma processing and contributes to reducing dependence on overseas suppliers.
The Kolar unit is central to PlasmaGen’s ability to increase the availability of life‑saving plasma therapies domestically and to support consistent supply for specialised care centres and hospitals.
Investor backing and sector context
Investors in PlasmaGen include ViNS Bioproducts and established healthcare funds such as Eight Roads Ventures, F‑Prime Capital and FIL Capital Investments. Their participation reflects confidence in the commercial prospects for plasma therapeutics as demand for specialised biological treatments rises in India and globally.
As regulatory pathways and manufacturing scale evolve, private domestic capacity for plasma fractionation is expected to play a larger role in meeting clinical demand and lowering treatment costs, industry analysts say. PlasmaGen’s new funding round represents a strategic step toward building a more resilient and globally competitive plasma therapeutics ecosystem in India.
